By vgreene, 29 April, 2020 Study considerations: non-randomized, open-label study; excl older and severe pts; possible historical bias; relationship btwn viral titer and clinical prognosis not well defined
By vgreene, 29 April, 2020 Median time to viral clearance shorter in FPV pts (4 days vs 11 days); no difference in chest CT improvement rates on day 4 and 8, but higher rates seen in FPV pts on day 14 (91% vs 62%); higher CT improvement rates also assoc w/ pts w/
By vgreene, 29 April, 2020 Remdesivir in Adults With Severe COVID 19 A Randomised Double blind Placebo controlled Multicentre Trial
By vgreene, 29 April, 2020 Study considerations: underpowered due to low enrollment; imbalanced baseline characteristics despite randomization; possible delay in tx start; questionable utility of subgroup analyses
By vgreene, 29 April, 2020 Viral loads decreased at similar rates in both groups; ADRs similar btwn groups (RDV 66%, placebo 64%); higher D/C rates in RDV (12%) vs placebo (5%)